Researchers in Korea recently identified predictive factors for normalization of thyroid-stimulating immunoglobulin levels in moderate-to-severe Graves’ orbitopathy, highlighting the importance of ...

March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in late-stage study, when tested in patients with active thyroid eye disease. The injectable drug, ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The most useful biomarker for extraocular muscle enlargement in thyroid eye disease (TED) is unclear. According to this study, higher thyroid-stimulating antibody (TSAb) levels and older age were ...

Safety findings aligned with prior batoclimab experience, with no emergent safety liabilities reported across the phase 3 ...

Thyroid eye disease (TED), also known as Graves’ eye disease, usually stems from an autoimmune condition that starts when immune cells attack the thyroid gland, a tiny butterfly-shaped gland at the ...

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with ...

The leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. Most patients with thyroid eye ...

For sight-threatening thyroid eye disease (TED), both the European Group on Graves’ Orbitopathy guidelines and the American Thyroid Association and the European Thyroid Association (ATA/ETA) statement ...

In most cases, thyroid eye disease (TED) is associated with Graves’ disease (GD). Approximately 40% of patients with GD develop overt TED. However, a sub-clinical level of extraocular muscle ...

Graves’ disease is an autoimmune condition that causes hyperthyroidism, or too much thyroid hormone. Over time, high thyroid hormone levels can harm your heart, bones, skin, and eyes. Common ...

By Siddhi Mahatole March 30 (Reuters) - Viridian Therapeutics said on Monday its experimental drug met the main goal in a late-stage study, when tested in patients with active thyroid eye disease.